rly-4008,fgfr2 inhibitor
relay therapeutics,cogent biosciences
['fgfr2 inhibitor', 'rly-4008']
#icymi published at #asco23 rly-4008, the first highly selective #fgfr2 inhibitor with activity across fgfr2 alterations and resistance mutations, by , vaibhav sahai, jessica casaletto et al. 
Follow Cancer Discovery for high-impact articles and news covering major advances in basic, translational, and clinical cancer research. Published by @AACR.